Cargando…

Recirculating hyperthermic intravesical chemotherapy with mitomycin C (HIVEC) versus BCG in high-risk non-muscle-invasive bladder cancer: results of the HIVEC-HR randomized clinical trial

PURPOSE: The purpose of the study was to compare the outcomes of high-risk non-muscle-invasive bladder cancer (HR-NMIBC) patients treated with BCG vs recirculating hyperthermic intravesical chemotherapy (HIVEC) with mitomycin C (MMC). METHODS: A pilot phase II randomized clinical trial was conducted...

Descripción completa

Detalles Bibliográficos
Autores principales:	Guerrero-Ramos, Félix, González-Padilla, Daniel A., González-Díaz, Alejandro, de la Rosa-Kehrmann, Federico, Rodríguez-Antolín, Alfredo, Inman, Brant A., Villacampa-Aubá, Felipe
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8994727/ https://www.ncbi.nlm.nih.gov/pubmed/35037963 http://dx.doi.org/10.1007/s00345-022-03928-1

Ejemplares similares

Is CIS a Contraindication to Hyperthermic Intravesical Chemotherapy (HIVEC) after BCG-Failure?
por: Anastay, Vassili, et al.
Publicado: (2023)

A scalable hyperthermic intravesical chemotherapy (HIVEC) setup for rat models of bladder cancer
por: Van Hattum, J. W., et al.
Publicado: (2022)

Long-Term Experience with Hyperthermic Chemotherapy (HIVEC) Using Mitomycin-C in Patients with Non-Muscle Invasive Bladder Cancer in Spain
por: Plata, Ana, et al.
Publicado: (2021)

Impact of systemic inflammatory markers on the response to Hyperthermic IntraVEsical Chemotherapy (HIVEC) in patients with non-muscle-invasive bladder cancer after bacillus Calmette–Guérin failure
por: Chiancone, Francesco, et al.
Publicado: (2021)

Adjuvant intravesical chemohyperthermia or conventional chemotherapy in an era of bacillus Calmette-Guérin shortage for non-muscle invasive bladder cancer: The HIVEC-II trial
por: Bhargava, Priyank
Publicado: (2023)

Hyperthermic Intravesical Chemotherapy for BCG Unresponsive Non-Muscle Invasive Bladder Cancer Patients
por: de Jong, Joep J., et al.
Publicado: (2018)

Hyperthermic intravesical chemotherapy with mitomycin‐C for the treatment of high‐risk non‐muscle‐invasive bladder cancer patients
por: Conroy, Samantha, et al.
Publicado: (2022)

Hyperthermia as Adjunct to Intravesical Chemotherapy for Bladder Cancer
por: Owusu, Richmond A., et al.
Publicado: (2013)

Systemic BCG‐osis following intravesical BCG instillation for bladder carcinoma
por: Liaw, Frank, et al.
Publicado: (2017)

The use of intravesical BCG in urothelial carcinoma of the bladder
por: Alhunaidi, Omar, et al.
Publicado: (2019)

Intravesical Instillation of Mitomycin C: A Cause of Delayed Bladder Perforation?
por: Penna, Marta, et al.
Publicado: (2012)

Disseminated BCG: Complications of Intravesical Bladder Cancer Treatment
por: To, Uyen, et al.
Publicado: (2014)

BCG+MMC trial: adding mitomycin C to BCG as adjuvant intravesical therapy for high-risk, non-muscle-invasive bladder cancer: a randomised phase III trial (ANZUP 1301)
por: Hayne, Dickon, et al.
Publicado: (2015)

Pott's disease post intravesical BCG
por: Jain, Anika
Publicado: (2023)

Hyperthermic Intraperitoneal Chemotherapy and Recirculation with CO(2): A Safe Technique
por: Gómez-Sanz, Remedios, et al.
Publicado: (2022)

Outcomes and complications of Hyperthermic IntraVesical Chemotherapy using mitomycin C or epirubicin for patients with non-muscle invasive bladder cancer after bacillus Calmette-Guérin treatment failure
por: Chiancone, Francesco, et al.
Publicado: (2020)

Bladder Sparing Therapy for BCG Failures – I – Intravesical Immunotherapy
por: Messing, Edward M.
Publicado: (2017)

Mycobacteria Bovis osteomyelitis following intravesical BCG for bladder cancer
por: Seegobin, Karan, et al.
Publicado: (2017)

Autophagy Controls BCG-Induced Trained Immunity and the Response to Intravesical BCG Therapy for Bladder Cancer
por: Buffen, Kathrin, et al.
Publicado: (2014)

Asymptomatic renal BCG granulomatosis: An unusual complication of intravesical BCG therapy for carcinoma urinary bladder
por: Bhat, Suresh, et al.
Publicado: (2015)

Comparing adverse effects, short term outcomes, and cost implications of hyperthermic intravesical chemotherapy with Mitomycin-C and intravesical bacillus Calmette–Guerin instillation (Moscow-I strain) in the management of intermediate and high-risk nonmuscle invasive bladder cancer
por: Thyavihally, Yuvaraja B., et al.
Publicado: (2021)

Solubilization and Stability of Mitomycin C Solutions Prepared for Intravesical Administration
por: Myers, Alan L., et al.
Publicado: (2017)

Incidence, Risk Factors, and Impact of Severe Neutropenia After Hyperthermic Intraperitoneal Mitomycin C
por: Lambert, Laura A., et al.
Publicado: (2009)

Systemic BCG-Osis as a Rare Side Effect of Intravesical BCG Treatment for Superficial Bladder Cancer
por: Lukacs, S., et al.
Publicado: (2013)

Discriminators of mouse bladder response to intravesical Bacillus Calmette-Guerin (BCG)
por: Saban, Marcia R, et al.
Publicado: (2007)

Mycobacterial Osteomyelitis of the Spine Following Intravesical BCG Therapy for Bladder Cancer
por: Mackel, Charles E, et al.
Publicado: (2016)

Role of Intravesical BCG as a Therapeutic Vaccine for Treatment of Bladder Carcinoma
por: Doroud, Delaram, et al.
Publicado: (2022)

Challenges to Improve the Stability and Efficacy of an Intravesical BCG Product
por: Hozouri, Hamidreza, et al.
Publicado: (2014)

Protective role of intravesical BCG in COVID-19 severity
por: Gallegos, Héctor, et al.
Publicado: (2021)

An uncommon cause of miliary disease: intravesical BCG immunotherapy
por: Azevedo, Marcelo, et al.
Publicado: (2021)

Redefining the role of immediate intravesical instillation of mitomycin C in non-muscle invasive bladder cancer
por: Batura, Deepak
Publicado: (2018)

Hyperthermia Improves Solubility of Intravesical Chemotherapeutic Agents
por: Grimberg, Dominic C., et al.
Publicado: (2020)

Clarification of Bladder Cancer Disease States Following Treatment of Patients with Intravesical BCG
Publicado: (2015)

Intravesical ALT-803 for BCG-unresponsive Bladder Cancer – A Case Report
por: Huang, Jeffrey, et al.
Publicado: (2017)

Multisystemic BCGitis: A rare complication of intravesical BCG immunotherapy for bladder cancer
por: Vilares, Ana T., et al.
Publicado: (2022)

Adjuvant Hyperthermic Intravesical Chemotherapy in Intermediate- and High-Risk Non-muscle Invasive Bladder Cancer
por: Magalhães, Joana C, et al.
Publicado: (2023)

A rare complication of intravesical early instillation of mitomycin C after TURBT
por: Hatem, Humam, et al.
Publicado: (2019)

Case Presentation: Lung Consolidation as Sequelae of BCG Sepsis After Combined Intravesical and Intraurethral BCG
por: Strich, Jeffrey R., et al.
Publicado: (2017)

Intravesical hyperthermia and mitomycin-C for carcinoma in situ of the urinary bladder: experience of the European Synergo(®) working party
por: Alfred Witjes, J., et al.
Publicado: (2009)

Editorial on the value of an immediate intravesical instillation of mitomycin C in patients with non-muscle-invasive bladder cancer
por: Oosterlinck, Willem, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_a8sda0nlppgpne0ubo9ekbd4q6